TABLE 4.
Crude (OR) and adjusted odds ratio (aOR) of the association between every dose increase in number of anti-SARS-CoV-2 vaccine doses and boosting status with having ≥median concentration of anti-S IgG (≥357.5 BAU/ml), anti-N IgG (≥146.5 COI), and neutralizing IgG (≥172.0 AU/ml) antibodies and having a T-cell response.
| Anti-S IgG Abs (≥median vs. <median concentration) |
Anti-N IgG Abs (≥median vs. <median concentration) |
Neutralizing IgG Abs (≥median vs. <median concentration) |
T-cell response (Yes vs. No) |
|||||
|
OR (95% CI) |
aOR (95% CI) |
OR (95% CI) |
aOR (95% CI) |
OR (95% CI) |
aOR (95% CI) |
OR (95% CI) |
aOR (95% CI) |
|
| Additional one vaccine dose | 1.22 (0.98–1.53) |
1.34 (1.02–1.76)* |
1.55 (1.22–1.97)*** |
1.35 (1.03–1.75)* |
1.15 (0.92–1.44) |
1.29 (1.00–1.66)* |
1.26 (0.99–1.60) |
1.48 (1.12–1.95)** |
| Booster status1 | ||||||||
| Not boosted (primed with only two doses) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Boosted once (received three doses) | 0.95 (0.69–130) |
0.90 (0.65–1.25) |
2.28 (1.64–2.18)*** |
2.17 (1.54–3.1)*** |
0.80 (0.59–1.10) |
0.78 (0.56–1.09) |
1.10 (0.80–1.55) |
1.07 (0.76–1.51) |
| Boosted twice (received four doses) | 20.0 (2.63–152.0)** |
14.20 (1.85–109.4)* |
1.43 (0.57–3.57) |
1.27 (0.48–3.36) |
17.30 (2.27–131.36)*** |
13.60 (1.77–104.3)* |
9.70 (2.272–34.50)*** |
7.62 (2.09–27.87)** |
| Vaccine type–only vaccinated2 | ||||||||
| BBIBP-CorV only | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Primed with BBIBP-CorV boosted with BNT162b2 | 7.39 (2.86–19.09)*** |
7.57 (2.61–21.94)*** |
0.54 (0.27–1.06) |
0.48 (0.23–1.0) |
7.32 (2.83–18.9)*** |
7.86 (2.71–22.83)*** |
4.72 (2.25–9.90)*** |
4.28 (1.93–9.50)*** |
| rAd26-S + rAd5-S only | NA | NA | NA | NA | NA | NA | 0.97 (0.32–2.92) |
1.13 (0.36–3.60) |
| Others3 | 10.01 (1.27–79.8)* |
9.95 (1.23–80.65)* |
0.10 (0.01–0.81)* |
0.14 (0.02–1.1) |
4.41 (0.94–21.0) |
4.14 (0.85–20.14) |
7.00 (1.48–33.12)* |
7.90 (1.63–38.6)* |
| Others4 | 25.74 (3.46–191.41)** |
29.52 (3.9–223.9)*** |
0.04 (0.005–0.30)** |
0.06 (0.01–0.48)** |
25.73 (3.50–191.41)*** |
13.52 (3.06–59.2)*** |
2.07 (0.91–4.70) |
2.46 (1.03–5.9)* |
Adjusted odds ratio for age (continuous), BMI (continuous), type of vaccine, smoking status, chronic comorbidity, time duration since last vaccine dose, and history of previous infection (PCR+).
1Adjusted also for type of vaccine.
2Adjusted also for total number of vaccine doses.
3Three of them received only BNT162b2, and the rest received heterogeneous vaccine types.
4Three of them received only BNT162b2, and 14 received only rAd26-S + rAd5-S. The rest received heterogeneous vaccine types.
***P < 0.001, **P = 0.002, and *P < 0.005.